Haijun Zhang

Prof. Dr. Haijun Zhang

Zhongda Hospital Affiliated to Southeast University
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in Medicine
Verified
Journal Article
Open access
YAYaser Alduais
Yaser Alduais
HZHaijun Zhang
Haijun Zhang
FFFan Fan
Fan Fan
JCJing Chen
Jing Chen
BCBaoan Chen
Baoan Chen
Lung cancer remains the leading cause of cancer deaths. Non-small cell lung cancer (NSCLC) is the most frequent subtype of lung cancer. Surgery, radiation, chemotherapy, immunotherapy, or molecularly targeted therapy is used to treat NSCLC. Nevertheless, many patients who accept surgery likely develop distant metastases or local recurrence. In recent years, targeted treatments and immunotherapy have achieved improvement at a breakneck pace. Therapy must be customized for each patient based on the specific medical condition, as well as other variables. It is critical to have an accurate NSCLC sub-classification for tailored treatment, according to the latest World Health Organization standards.

1 March 2011 in Biomaterials
Verified
Journal Article
Closed access
HZHaijun Zhang
Haijun Zhang
BCBaoan Chen
Baoan Chen
HJHui Jiang
Hui Jiang
CWCailian Wang
Cailian Wang
HWHuangping Wang
Huangping Wang
XWXuemei Wang
Xuemei Wang

1 November 2015 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HZHaijun Zhang
Haijun Zhang
As tumor angiogenesis is one of the hallmarks of cancer, the inhibition of vascular endothelial growth factor signaling has become an attractive anticancer approach. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2, has demonstrated encouraging anticancer activity across a broad range of malignancies, including gastric cancer, non-small-cell lung cancer, breast cancer, and hepatocellular carcinoma. In this up-to-date review, focus is not only on the structure, mechanisms, and pharmacokinetics of apatinib, but also on summarizing clinical trials and making recommendations of apatinib for patients with advanced solid tumors.

1 May 2016 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
HZHaijun Zhang
Haijun Zhang
Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a broad range of malignancies, including pancreatic cancer, esophago-gastric cancer, and colorectal cancer. This up-to-date review not only focuses on the structure, pharmacokinetics, and pharmacogenetics of Onivyde but also summarizes clinical trials and recommends Onivyde for patients with advanced solid tumors.

1 August 2014 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
HZHaijun Zhang
Haijun Zhang
YSYongfeng Shan
Yongfeng Shan
LDLijun Dong
Lijun Dong
The TiO2 and ZnO nanoparticles are the most promising next-generation photodynamic therapy (PDT) photosensitizers. This paper reports a one-to-one comparison of TiO2 and ZnO nanoparticles as photosensitizers in photodynamic therapy of cancer. After incubating SMMC-7721 hepatocarcinoma cells with TiO2 and ZnO nanoparticles, we irradiated the cells with ultraviolet (UV) light and formation of intracellular reactive oxygen species (ROS) was monitored using the dichloro-dihydro-fluorescein diacetate (DCFH-DA) method. The cytotoxicities of ZnO and TiO2 nanoparticles as photosensitizers in cancer PDT were evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Furthermore, the mRNA and protein expression levels of apoptosis-related gene, including Bax, Bcl-2, and Caspase 3 were examined using RT-PCR and Western blot to elucidate the possible molecular mechanisms involved. Our results demonstrated that both TiO2 and ZnO nanoparticles could generate ROS within the tumor cells after irradiation, which in turn could attack the cancer cells. The caspase-dependent apoptosis was thus induced, resulting in anticancer activity. When the therapeutic effects were compared, no differences between the TiO2 and ZnO nanoparticles were observed for PDT. Either TiO2 or ZnO nanoparticles can therefore be used in the near future as alternative photosensitizers in targeted tumor PDT when light is directly focused on the lesion.

1 September 2016 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
HZHaijun Zhang
Haijun Zhang
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for advanced non-small-cell lung cancer that harbors sensitizing EGFR mutations (EGFRm+) such as exon 19 deletions and L858R substitutions in exon 21. However, acquired resistance to EGFR TKIs is mostly driven by a second-site EGFR T790M mutation, which negates their inhibitory activity. Osimertinib (AZD9291, Tagrisso™), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. In this up-to-date review, focus is not only on the structure, mechanisms, and pharmacokinetics of osimertinib but also on summarizing clinical trials and making recommendations of osimertinib for patients with non-small-cell lung cancer.